2019 CONGRESS OF THE SCHIZOPHRENIA INTERNATIONAL RESEARCH SOCIETY

United in Progress

10-14 APRIL, 2019
HYATT REGENCY
ORLANDO, FLORIDA
Dear Attendees,

It is our great pleasure to welcome you to the 2019 Congress of the Schizophrenia International Research Society. SIRS is a non-profit organization dedicated to promoting research and communication about schizophrenia among research scientists, clinicians, drug developers, and policy makers internationally. We sincerely appreciate your interest in the Society and in our conference. The 2018 congress that took place in Florence, Italy continued to be a very successful congress to date attracting more than 1500 researchers from 54 countries. As the 2019 Congress will be the first North American congress, we believe the meeting will draw even higher calibre researchers in the field of schizophrenia.

SIRS was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society is dedicated to facilitating international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new research on schizophrenia.

The focus of the 2019 Congress is, “United in Progress”. The theme suggests the need for the truly integrative and collaborative approach needed to significantly move forward the direction of schizophrenia research. The Congress brings together leaders from major academic and clinical centres across the world and aims to bring impetus to the identification of new targets and psychological models that will advance research and development of new preventative and treatment strategies.

Under the outstanding leadership of Program Committee Chairs, Paola Dazzan and Raquel Gur, we have an exciting scientific program planned for this year. The program features seven plenary speakers who will cover new directions in schizophrenia research, as well as the use of innovative approaches to treatment and data analyses. The Program Committee selected thirty-four outstanding symposia sessions and 103 superior oral presentations. The program also contains a Pharmaceutical Pipeline session to be presented on Thursday. Plan to visit the poster sessions during lunch on Thursday, Friday, and Saturday to see the over 450 poster presentations.

Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference and in addition to learning about the latest, cutting edge research in the field, you will enjoy your time in Orlando.

Sincerely,

The Organizers

President: Lynn DeLisi, M.D.
President-elect: Til Wykes, DBE, MPhil, Ph.D.
Past President: Patrick McGorry, FRCP, M.D., Ph.D.
Secretary: Paola Dazzan, M.D., Ph.D., FRCPscyh
Treasurer: Robert Buchanan, M.D.
Program Committee Chair: Raquel Gur, M.D. Ph.D.
<table>
<thead>
<tr>
<th>Table of Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disclosures</td>
<td>2</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>2</td>
</tr>
<tr>
<td>Officers, Board and Advisory Council</td>
<td>3</td>
</tr>
<tr>
<td>2018-2020 Committees</td>
<td>4</td>
</tr>
<tr>
<td>Continuing Medical Education</td>
<td>6</td>
</tr>
<tr>
<td>General Information</td>
<td>8</td>
</tr>
<tr>
<td>Awards</td>
<td>9</td>
</tr>
<tr>
<td>Plenary Sessions</td>
<td>19</td>
</tr>
<tr>
<td>Symposia Sessions</td>
<td>20</td>
</tr>
<tr>
<td>Oral Presentations</td>
<td>20</td>
</tr>
<tr>
<td>Posters</td>
<td>20</td>
</tr>
<tr>
<td>Floor Plan</td>
<td>21</td>
</tr>
</tbody>
</table>
Disclosures

Disclosures for 2019 speakers, plenary, symposia, oral presentations and poster presenters may be found online. Click here for disclosures. A copy of the disclosures will be available at the registration desk.

Acknowledgements

The Schizophrenia International Research Society appreciates the generous support of the Society from our 2019 Supporting Corporations.

Gold

Silver

Other Sponsorships

Intra-Cellular Therapies

Educational Grants:
The Society expresses appreciation to the following company for their support of this educational activity by providing unrestricted educational grants:

Sunovion
Officers, Board and Advisory Council

OFFICERS:

Lynn DeLisi  
M.D.  
President

Til Wykes  
Ph.D.  
President-elect

Patrick McGorry  
FRCP, M.D., Ph.D.  
Past-President

Paola Dazzan  
M.D., Ph.D., FRCPsych  
Secretary

Robert Buchanan  
M.D.  
Treasurer

BOARD OF DIRECTORS (2018-2020):

Peter Buckley, United States
Kim Do, Switzerland
Peter Falkai, Germany
Silvana Galderisi, Italy
Richard Keefe, United States
Robin Murray, United Kingdom
Merete Nordentoft, Denmark
Sohee Park, United States
Susan Rossell, Australia
Nina Schooler, United States
Iris Sommer, the Netherlands
Dawn Velligan, United States
Mark Weiser, Israel
INTERNATIONAL ADVISORY COUNCIL

Jean Addington, Canada  
Deanna Barch, USA  
Alessandro Bertolino, Italy  
Mary Cannon, Ireland  
David Castle, Australia  
Eric Chen, China  
Christoph Correll, USA  
Christina Dalman, Sweden  
Anthony David, United Kingdom  
F.W. Deakin, United Kingdom  
Wolfgang Fleishhacker, Austria  
Kyung Sue Hong, Republic of Korea  
Matti Hutunen, Finland  
James Kennedy, Canada  
Shon Lewis, United Kingdom  
Mario Maj, Italy  
John McGrath, Australia  
Paulo Menezes, Brazil  
Preben Mortensen, Denmark  
Patricio O’Donnell, USA  
Emmanuelle Peters, United Kingdom  
Anita Riecher-Rössler, Switzerland  
Sibylle Schwab, Germany

2018-2020 Committees

AWARDS COMMITTEE

Celso Arango, Chair  
Vera Morgan, Co-Chair  
Anne Bassett  
Stefan Borgwardt  
David Braff  
Robin Emsley  
Henry Nasrallah  
Christos Pantelis  
Til Wykes

DIVERSITY TASK FORCE

Sohee Park, Chair  
Raymond Chan  
Lynn DeLisi  
Elisa Dias  
Vina Goghari  
Diane Gooding  
Melissa Green  
Yasmin Hurd  
Alice Medalia  
Margaret Niznikiewicz

EDUCATION COMMITTEE

Robin Emsley, Chair  
Laila Asmal, Co-Chair  
Mario Alvarez-Jimenez, Co-Chair  
Elisabetta del Re  
Faith Dickerson  
Tzung-Jeng Hwang  
Sanja Kilian  
Brian O’Donoghue  
Susana Ochoa  
Nina Schooler  
Clement Zai

ETHICS COMMITTEE

Stephen Marder, Chair  
Silke Bachmann, Co-Chair  
Larry Alphs  
Karolina Bryl  
Deborah Levy  
Richard Linscott  
Rick Mofsen  
Vaidy Swaminathan
FINANCIAL COMMITTEE
Robert Buchanan, Chair
Shitij Kapur, Co-Chair
William Byerley
Lynn DeLisi
Philip Harvey
Jean-Pierre Lindenmayer
Robin Murray
Cynthia Shannon Weickert

FUNDRAISING TASK FORCE
Lynn DeLisi
Robert Buchanan
Mahavir Agarwal
Mariana Calzavara
Dan Devoe
Maria Di Biase
Patrick McGorry

MEMBERSHIP COMMITTEE
Paola Dazzan, Chair
Sybille Schwab, Co-Chair
Andrea de Bartolomeis
Michael Harte
James MacCabe

PUBLICATION COMMITTEE
Silvana Galderisi, Chair
Eric Chen, Co-Chair
Susan Cotton
Peter Falkai
Vina Goghari
Mari Hansen
Matcheri Keshavan
Marek Kabicki
James Meador-Woodruff
Dost Ongur
Thomas Weickert

2019 PROGRAM COMMITTEE
Paola Dazzan, Co-Chair
Raquel Gur, Co-Chair
Monica Aas
Anissa Abi-Dargham
Celso Arango
Stefan Borgwardt
Rodrigo Bressan
Robert Buchanan
Mary Cannon
Susan Cotton
Paola Dazzan
Brian Dean
Lynn DeLisi
Peter Falkai
Vina Goghari
Diane Gooding
Anthony Grace
Melissa Green
Ronald Gurrera
Philip Harvey
Kenji Hashimoto
Felice Iasevoli
René Kahn
Matcheri Keshavan
Patrick McGorry
James Meador-Woodruff
Alice Medalia
Ingrid Melle
Vijay Mittal
Bita Moghaddam
Craig Morgan
Robin Murray
Barnaby Nelson
Margaret Niznikiewicz
Susana Ochoa
Sohee Park
Maxine Patel
Diana Perkins
Emmanuelle Peters
Susan Rossell
Jean-Paul Selten
Jaana Suvisaari
Si Tianmei
Neeltje Van Haren
Til Wykes
TianHong Zhang
Continuing Medical Education

*International CME Accreditation

The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for a maximum of 24 AMA PRA Category 1 Credits™. ACCME / AMA PRA Category 1 Credits™ carry reciprocity with EACCME member countries and most international licensing bodies for physicians, with some exceptions. Physicians should check with their country/board for eligibility.

SATISFACTORY COMPLETION

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

PHYSICIANS

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Schizophrenia International Research Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 24 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To obtain credit, registered participants must complete an online evaluation at the conclusion of the meeting. The evaluation may be completed at www.SchizophreniaConference.org.
COURSE OBJECTIVES:

After participating in the CME Activity, Clinicians should be able to describe and discuss:

- Strategies for determining an approach to manage patients with schizophrenia
- The Status of genetic findings, and how they can be incorporated into strategies for managing patients with schizophrenia
- The use of brain imaging data about pathophysiology and disease progression to revise or continue a strategy for managing patients with schizophrenia
- The implications of basic neuroscience findings for managing patients with schizophrenia

After participating in the CME Activity, Researchers should be able to describe and discuss:

- Approaches to develop novel treatments for schizophrenia
- Strategies for translating basic neuroscience into knowledge that can be used in clinical practice
- Differences in schizophrenia research across diverse cultures and geographic areas
- Novel intervention studies that will promote the development of advanced knowledge about schizophrenia
- Methods to advance the clinical application of genetic research in schizophrenia

DISCLOSURES

Disclosures for 2019 speakers, plenary, symposia, oral presentations and poster presenters may be found in the mobile app and online. A copy of the disclosures will be available at the registration desk.

CONFERENCE EVALUATION:

All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACCME, EACCME) credit for the meeting are required to complete the evaluation. This form is available online only. Beginning 14 April, you may complete the evaluation online at www.SchizophreniaConference.org. All evaluations must be completed by Tuesday, 14 May 2019.

VIDEOTAPING SESSIONS:

Attendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.
General Information

REGISTRATION
Registration for the 2019 Congress of the Schizophrenia International Research Society is located in the Regency P-Q Foyer.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, 10 April</td>
<td>11:00 AM – 7:30 PM</td>
</tr>
<tr>
<td>Thursday, 11 April</td>
<td>7:00 AM – 7:30 PM</td>
</tr>
<tr>
<td>Friday, 12 April</td>
<td>7:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Saturday, 13 April</td>
<td>7:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Sunday, 14 April</td>
<td>7:00 AM – 12:00 PM</td>
</tr>
</tbody>
</table>

REGISTRATION TYPES:
Delegate: Scientific Attendee
Student: Full-time graduate students, medical students, or students in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research. A letter from the student’s immediate supervisor verifying his/her student status and relevant field will be required for registration.

REGISTRATION FEES:

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Early Bird Rate Deadline: 11 January 2019</th>
<th>Standard Rate Starts 12 January 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIRS Member Delegate</td>
<td>$560</td>
<td>$610</td>
</tr>
<tr>
<td>SIRS Student Member Delegate</td>
<td>$240</td>
<td>$290</td>
</tr>
<tr>
<td>Non-Member Delegate</td>
<td>$800</td>
<td>$850</td>
</tr>
<tr>
<td>Non-Member Student Delegate</td>
<td>$280</td>
<td>$330</td>
</tr>
<tr>
<td>Accompanying Person</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Guest Ticket for Opening Reception</td>
<td>$50</td>
<td>$50</td>
</tr>
</tbody>
</table>
SPEAKER READY ROOM

A speaker ready room is available in Blue Spring in the Hyatt Regency Orlando. All presenters are required to come to the speaker ready room to upload your presentation, preferably 24-hours prior to the presentation. Presentations from individual computers are not permitted. Below are the hours for the Speaker Ready Room:

**Speaker Ready Room**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 11 April</td>
<td>7:00 AM – 5:00 PM</td>
</tr>
<tr>
<td>Friday, 12 April</td>
<td>7:00 AM – 5:00 PM</td>
</tr>
<tr>
<td>Saturday, 13 April</td>
<td>7:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Sunday, 14 April</td>
<td>7:00 AM – 11:30 AM</td>
</tr>
</tbody>
</table>

ABSTRACTS:

Abstracts for all presentations are available online. Click here to access the Online Congress Schedule. Abstracts will be published electronically by Oxford and will be available as an electronic flipbook and as a PDF document.

Awards

The Awards Committee and Board of Directors of the Schizophrenia International Research Society are pleased to announce the Society's Honorific Award Winners.

**SIRS LIFETIME ACHIEVEMENT AWARD**

William T. Carpenter, Jr., M.D.

William T. Carpenter, Jr., M.D., is a Professor of the University of Maryland School of Medicine and past Director (1977-2013) of the Maryland Psychiatric Research Center (MPRC). He obtained his medical degree from the Wake Forest University School of Medicine. After an internship at the North Carolina Baptist Hospital, he undertook postgraduate training at the University of Rochester Strong Memorial Hospital. He began his research career with the National Institute of Mental Health Intramural Research Program in 1966, using neuroendocrine strategies to study the psychobiology of affective disorders. Since 1968 his career has focused on the care and study of persons with schizophrenia. First with the World Health Organization’s International Pilot Study of Schizophrenia and an inpatient unit at NIH, then briefly at the Albert Einstein College of Medicine and Columbia College of Physicians and Surgeons before establishing schizophrenia research at the MPRC. Dr. Carpenter is the Editor-in-Chief for *Schizophrenia*.

continued on next page
William T. Carpenter, Jr., M.D. (continued)

Bulletin and has served on many editorial boards and advisory committees, and has authored over 400 publications. Dr. Carpenter is Past-President of the American College of Neuropsychopharmacology and initiated the founding of the National Alliance for Research on Schizophrenia and Depression (NARSAD), now the Brain and Behavior Research Foundation where he chairs the scientific program committee. He serves as a senior advisor for NIMH.

Dr. Carpenter’s professional interest includes phenomenology, etiology, pathophysiology, anatomy, and treatment. He has made original and fundamental contributions in psychopathology, assessment methodology, testing of novel treatments, and research ethics. Dr. Carpenter has served as Principle Investigator on five NIMH-funded center grants and three NARSAD Distinguished Investigator awards. He provided expert testimony in the case of the United States Government v. John Hinckley and in 1989 was a member of the State Department delegation to inspect the political use of psychiatry in the Soviet Union. He chaired the work group responsible for psychotic disorders for DSM-5. He has been the recipient of numerous national and international honorific awards beginning with the 1979 Stanley R. Dean Award for Psychiatric Research, including the Lieber Prize from NARSAD in 2000, the 2009 NAMI Mind of America Scientific Research Award and in 2013, the Menninger Award from the American College of Physicians and the Adolph Meyer Award from the American Psychiatric Association. Dr. Carpenter was elected to the Institute of Medicine of the National Academy of Sciences in 1998 and in 2013 was awarded The Rhoda and Bernard Sarnat International Prize in Mental Health by the National Academy of Medicine.

SIRS DISTINGUISHED SERVICE AWARD

Jean Addington, Ph.D.

Jean Addington, Ph.D. is Professor of Psychiatry at the University of Calgary in Alberta, Canada where she holds the Novartis Chair for Schizophrenia Research. Her research interests are in early detection and intervention in psychosis. Currently her major research focus is the examination of predictors of conversion to psychosis and the development of psychosocial interventions for those at clinical high risk of developing psychosis. She is one of the principal investigators in the North American Prodrome Longitudinal Study (NAPLS) and holds an NIMH grant to determine predictors and mechanisms of developing psychosis. She leads an NIMH funded RCT of Cognitive Behavioral Social Skills Training for clinical high risk. Additionally, she has received funding from Brain Canada to examine predictors of serious mental illness in youth at risk.
John M. Kane, M.D.

John M. Kane, MD, is Senior Vice President for Behavioral Health Services at Northwell Health. He is Professor and Chairman of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Hempstead, New York and Chairman of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Dr. Kane received a BA from Cornell University and his medical degree from New York University School of Medicine.

Dr. Kane is the recipient of the Lieber Prize, The APA’s Kempf Award, Gralnick Award and Foundations Fund Prize, and The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology and the Schizophrenia International Research Society. Dr. Kane has been the principal investigator for 19 NIMH-funded research projects focusing on schizophrenia psychobiology, treatment and recovery, as well as improving the timeliness, quality and cost of care. He is the author of over 600 peer-reviewed papers and has an H-index of over 90. He also serves on the editorial boards of numerous journals.

OUTSTANDING BASIC RESEARCH

Brian Dean, Ph.D.

Brian Dean currently holds the positions of Head, The Molecular Psychiatry Laboratory and Deputy Director of the Victorian Brain Bank at The Florey, Professorial Research Fellow at the Centre for Mental Health, Swinburne University and Professorial Fellow in the Department of Florey Neuroscience and Mental Health, the University of Melbourne. Brian completed his studies for a Doctoral Degree at the University of Melbourne. Those studies and his subsequent research have been directed to understanding how changes in cellular biology can affect brain function to cause the symptoms of schizophrenia. In pursuit of this mission, Brian has sort to identify changes in the molecular cytoarchitecture of postmortem CNS from subjects with schizophrenia and understand how such changes will impact on biochemical pathways controlling brain function. Hence, among over 250 peer reviewed papers Brian has published significant bodies of work contributing to an understanding of the roles of muscarinic receptors, serotonin receptors and cytokine-regulated pathways in the aetiology and treatment of schizophrenia. More recently, Brian has begun to publish findings on omnibus changes in cortical gene expression in schizophrenia. In translating some of this work into the clinical arena, Brian is now collaborating with clinical colleagues to use a newly synthesised PET muscarinic receptor radioligand to study CNS receptor levels in schizophrenia and to use a newly discovered technology to develop a diagnostic test for the disorder. In recognition of his contribution to the field, Brian was admitted as a Fellow of the Royal Society of Biology. He has received honours including presenting the University of Melbourne Beattie Smith Lecture and the ASPR Lilly Oration. Brian has made significant contributions to his discipline that include being the Founder and Inaugural President of Biological

continued on next page
Brian Dean, Ph.D. (continued)

Psychiatry Australia, President of the Melbourne Chapter of the Society of Neuroscience, Treasurer of the CINP, Secretary of the Asian College of Schizophrenia Research and has served on CINP, SIRS and ASPR Committees. Brian is currently on the Board and about to become Treasurer of the Australian Society for Neuroscience. Finally, Brian is a Director and Chairman of the Scientific Advisory Committee of the Rebecca Cooper Medical Research Foundation which has a particular focus on funding early career researchers investigating brain disorders.

OUSTANDING CLINICAL/COMMUNITY RESEARCH

Keith H. Nuechterlein, Ph.D.

Keith H. Nuechterlein, Ph.D., is a Distinguished Professor in the Departments of Psychiatry and Biobehavioral Sciences and of Psychology at the University of California, Los Angeles. He serves as the Director of the UCLA Aftercare Research Program, a clinic devoted to clinical research and treatment with patients who have had a recent onset of schizophrenia. He served as the Director of the UCLA Center for Neurocognition and Emotion in Schizophrenia from 2003–2016. Dr. Nuechterlein received his B.A. in psychology and his Ph.D. in Psychology (Clinical) from the University of Minnesota. Dr. Nuechterlein has authored more than 300 journal articles and is among the scientists on the Clarivate Analytics Highly Cited list for Psychology/Psychiatry, indicating publications in the top 1% of citations. He has been on the editorial boards of the Journal of Abnormal Psychology and Schizophrenia Bulletin and is currently on the editorial board of Psychological Medicine. He has received numerous research grants from NIMH and other sources and has directed three NIMH training grants to help to develop young clinical researchers.

Dr. Nuechterlein is a past President of the Society for Research in Psychopathology and was named an Alumnus of Notable Achievement by the University of Minnesota. He was selected for the Zubin Lifetime Achievement Award by the Society for Research in Psychopathology, the Kraepelin-Alzheimer Medal by the University of Munich, and the Trail Blazer Award by the ABCT Special Interest Group on Schizophrenia.

One of his primary research efforts involves multidisciplinary longitudinal studies of contributors to and interventions for the early course of schizophrenia, with particular emphasis on cognition and functional outcome. He has demonstrated the significant contributions of supported employment/education, cognitive training, aerobic exercise, and long-acting antipsychotic medications for improving clinical outcome, cognition, and work recovery in early phases of schizophrenia. Another major focus is research to identify the cognitive factors in genetic vulnerability to schizophrenia and related disorders.

Dr. Nuechterlein served as the Co-Chair of the Neurocognition Committee for the NIMH-funded initiative, Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS). This group guided the development of the MATRICS Consensus Cognitive Battery, considered by the U.S. FDA to be the gold standard for assessing the impact of new interventions on core cognitive deficits in schizophrenia.
OUTSTANDING TRANSLATIONAL RESEARCH

Raquel Gur, M.D., Ph.D.

Dr. Gur is the Karl and Linda Rickels Professor of Psychiatry, Vice Chair for CHOP-Penn Research Integration, Co-Director of the Penn Translational Neuroscience Center and, Director of the Lifespan Brain Institute at the University of Pennsylvania School of Medicine and the Children’s Hospital of Philadelphia. She holds secondary professorial appointments in the Departments of Neurology and Radiology.

Her combined training in Psychology, Neurology and Psychiatry has provided the tools to pursue an academic career working with basic and clinical neuroscientists to advance the understanding of schizophrenia. In directing these research endeavors, she has interacted with scientists of diverse backgrounds, conducted collaborative interdisciplinary research, mentored junior faculty and trainees, and has come to know many patients and their families.

She is a member and has served in organizations including the Institute of Medicine of the National Academy of Sciences, the NIMH Council and the American Psychiatric Association task forces including the DSM-5 Psychosis work group. She is Past President of both the Society of Biological Psychiatry and the American College of Neuropsychopharmacology. NIMH has supported her research efforts and she has over 550 publications in peer-reviewed journals.

Ruben Gur, Ph.D.

Dr. Gur received his B.A. in Psychology and Philosophy from the Hebrew University of Jerusalem, Israel, in 1970 and his M.A. and Ph.D. in Psychology (Clinical) from Michigan State University in 1971 and 1973, respectively. He did Postdoctoral training with E.R. Hilgard at Stanford University and came to Penn as Assistant Professor in 1974. His research has been in the study of brain and behavior in healthy people and patients with brain disorders, with a special emphasis on exploiting neuroimaging as experimental probes. As Professor in the Departments of Psychiatry, Radiology & Neurology, and Director of the Brain Behavior Laboratory and the Center for Neuroimaging in Psychiatry, he has developed tools for “deep phenotyping” of brain and behavioral parameters using computerized acquisition tools that can integrate clinical and neurocognitive measures with neuroimaging and genomic data within the framework of large multicenter studies. His work has documented sex differences, aging effects, and abnormalities in regional brain function associated with schizophrenia, affective disorders, stroke, epilepsy, movement disorders and dementia. His work has been supported by grants from the NIMH, NIH, NIA, NINDS, NSF, DOD, NASA, private foundations (Spencer, MacArthur, EJLB, Brain and Behavior Research Foundation) and industry (Pfizer, AstraZeneca, Lilly, Merck).
RISING STAR

Gemma Modinos, Ph.D., FYAE
Photo Credit: Paul Musso

Dr. Modinos studied a BSc in Psychology followed by an MSc in Neuroscience in Barcelona (Spain). She then moved to the Netherlands, where she completed a PhD in Neuroscience (with Cum Laude distinction), supervised by Prof. André Aleman and Prof. Johan Ormel at the University of Groningen. As a post-doc, she moved to the UK to continue her academic career with Prof. Philip McGuire at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London (KCL). In 2013, she received a NARSAD Young Investigator Award to examine interactions between neurophysiology and neurochemistry within emotion-related neural circuitry in schizotypy. In 2016, she was awarded a KCL Prize Fellowship, which facilitated her transition to independence, and shortly after she received a Wellcome Trust & Royal Society Sir Henry Dale Fellowship, enabling the start of her own lab at the IoPPN. The lab combines multimodal neuroimaging methods in humans and animal models to ask questions about the interactions between neurochemistry, neurophysiology and neuroanatomy in the development of psychosis, with a focus on brain circuits involved in emotional processing. Dr. Modinos is also Honorary Senior Lecturer in the Departments of Psychosis Studies and Neuroimaging at the IoPPN, and Visiting Scholar at Prof. Anthony A. Grace’s lab at the University of Pittsburgh (USA). She chairs the ENIGMA Schizotypy Working Group with André Aleman, and she is involved in science policy as Fellow and Board Member of the Young Academy of Europe.

Panos Roussos, M.D., M.Sc., Ph.D.

Panos Roussos is an Associate Professor of Psychiatry and Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. He is a member of Icahn Institute – Genomics and Multiscale Biology and Friedman Brain Institute. He is also a VA/MIRECC Research Physician at the James J. Peters VA Medical Center. He received his medical and doctorate degrees from the University of Crete in Greece and he completed his residency in Psychiatry (research track) at Icahn School of Medicine at Mount Sinai followed by a MIRECC research fellowship in schizophrenia. His early research focused on the genetic exploration of intermediate cognitive phenotypes, including the prepulse inhibition of the startle reflex in human subjects and restoration of deficits using a pharmacogenomic approach. During his residency in psychiatry (Physician-Scientist Research Track) at Icahn School of Medicine at Mount Sinai, he worked on human postmortem studies by integrating genomics with gene expression and gene network approaches. His research focuses on the integration of high-dimensional data, such as genomic, epigenomic and transcriptomic, using advanced biostatistical methods in order to identify some of the mechanisms through which risk genetic variants increase the risk for neuropsychiatric diseases.
Jared Young, Ph.D.
Dr. Young received his Ph.D. at the University of Edinburgh in 2005, moving to UCSD in 2006 under the tutelage of Dr. Geyer bringing psychiatry-relevant cognitive testing in rodents to study cognitive dysfunction in schizophrenia. He has since created and reverse-translated numerous tests of cognition and behavior in rodents, producing a cross-species test-battery that combines fMRI and electroencephalographic measurement of brain function. This work led to his heavy involvement with the NIH-funded MATRICS, CNTRICS, and VA-sponsored MIRECC initiatives. After obtaining his first R21 to create and validate the highly translatable test of attention, the 5-choice CPT, Dr. Young joined the Faculty (2009). Since then, he has been fortunate to collaborate with many Departmental researchers, resulting in continued funding including NARSAD, R21s, R01s, and Center awards as Principal Investigator, plus Co-Investigator on others, many of which utilize tests he created and validated. His continued work identifying neural mechanisms underlying cognitive dysfunction for people living with schizophrenia, bipolar disorder, substance use disorders, and HIV, resulted in >130 publications plus awards including the Non-Clinical Psychopharmacologist of the Year (British Association Psychopharmacology; 2010), numerous Travel Awards (ACNP, SOBP, SIRS, ICOSR, IBNS among others), and American College of Neuropsychopharmacology membership (2016). He was recently voted as President of the International Behavioral Neuroscience Society (IBNS), where he will continue his support of clinically-relevant translational research.

SIRS PRESIDENT’S AWARD

Carol Tamminga, M.D.
Dr. Tamminga holds the Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry at the University of Texas Southwestern Medical School and is the Chairman of the Department of Psychiatry and the Chief of the Translational Neuroscience Division in Schizophrenia at UTSW. She received her M.D. degree from Vanderbilt University and completed residency training in psychiatry at the University of Chicago. She served on the University of Chicago faculty from 1975 to 1979 and moved to the NINDS for training in Neurology in 1978. After joining the faculty at the University of Maryland Medical School in 1979, she practiced research, clinical care and teaching there until joining the faculty at UT Southwestern Medical School in 2003.

Dr. Tamminga is currently a member of NIMH’s National Advisory Board and has served on the Board of Scientific Counselors of the National Institute of Mental Health and the National Institute of Drug Abuse, as Council member and President of the American College of Neuropsychopharmacology, as a Member and Chair of the Psychopharmacological Drugs Advisory Committee of the FDA, as well as consultant for the Orphan Products Development Review Group, FDA. She is a member of the Advisory Board of the Brain and Behavioral Research Foundation (NARSAD). She is currently the Deputy Editor of the American Journal of Psychiatry and on the editorial board of several other journals in the field. Dr. Tamminga was
Carol Tamminga, M.D. (continued)
elected to the Institute of Medicine of the National Academies of Sciences in 1998 and has served on several IOM committees in that capacity.

The goal of Dr. Tamminga’s research is to examine and understand the mechanisms underlying schizophrenia, especially its most prominent symptoms, psychosis and memory dysfunction, in order to build rational treatments for the illness. She evaluates the function of the living human brain in individuals with and without schizophrenia, using brain imaging techniques. Then, building on this knowledge, she uses human postmortem brain tissue to translate the functional alterations from the living human patient into molecular observations of the illness. Her ultimate goal is to base novel pharmacologies for psychosis and memory dysfunction on these observations and to use the altered in vivo imaging and postmortem molecular changes as biomarkers and targets for identifying animal models of disease and novel active pharmaceuticals.

POSTER AWARDS

npj Schizophrenia and Schizophrenia Bulletin will award poster prizes during the Closing Session on Sunday, 14 April at 9:30 AM. The SIRS Awards Committee will collaborate with journal editors to select the awards recipients. All three journals require that researchers be less than 40 years of age at the time of the conference for consideration.

SCHIZOPHRENIA RESEARCH FOUNDING EDITORS AWARD

Schizophrenia Research Founding Editors Award will recognize the best paper by both a Young Investigator and by a Senior Investigator. Each will be determined by the journal's Editors.

2019 GLOBAL SCHIZOPHRENIA AWARD

Alexandre Loch, M.D., Ph.D.
Dr. Loch is a Staff Psychiatrist, Institute of Psychiatry, University of São Paulo, Brazil. His current research is the Subclinical Symptoms and Psychosis Prodrome Project (SSAPP) which examines individuals at ultra-high risk for psychosis in the city of São Paulo.

Alexandra Zugno, Ph.D., Pharm.D.
Dr. Zugno is a professor and researcher for PPGCS (Programa de Pós Graduação em Ciências da Saúde – Post Graduation Course in Health Sciences). Her research studies the pathology and mechanisms of schizophrenia using various animal models.
CONGRATULATIONS TO THE 2019 TRAVEL AwarDEES:

Luis Alameda, United Kingdom
Abhishekh Ashok, United Kingdom
Suzanne Avery, United States
Ali Bani-Fatemi, Canada
Susan Berkhout, Canada
Mike Best, United States
Kelsey Bonfils, United States
Sidhant Chopra, Australia
Marco Colizzi, United Kingdom
Maria Dauvermann, Ireland
Stéfan Du Plessis, South Africa
Dominic Dwyer, Germany
Emily Eisner, United Kingdom
Alan Francis, United States
Suhas Ganesh, United States
Kiran Girdhar, United States
Dennis Hernaus, Netherlands
Dhruva Ithal, India
Sinead Kelly, United States
Chantel Kowalchuk, Canada
Tina Kristensen, Denmark

Katie Lavigne, Canada
Ellen Lee, United States
Imke Lemmers-Jansen, Netherlands
Brian O’Donoghue, Australia
Lindsay Oliver, Canada
Oladunni Olutayo, United States
Min Tae Park, Canada
Di Carlo Pasquale, Italy
Helena Passarelli Giroud Joaquim, Brazil
Ana Pinheiro, Portugal
Ian Ramsay, United States
Victoria Rodriguez, United Kingdom
Musa Sami, United Kingdom
Sunaina Soni, India
Susan Sonnenschein, United States
Jerome Taylor, United States
Michael Thomas, United States
Anna Waterreus, Australia
Jessica Wojtalik, United States
Zhuoya Yang, China

KEYNOTE LECTURE: JUDGE STEVEN LEIFMAN

Wednesday, 10 April, 6:00 PM – 7:15 PM

From 2007 – 2010, Miami-Dade County Judge Steve Leifman served as Special Advisor on Criminal Justice and Mental Health for the Supreme Court of Florida. In this capacity, Judge Leifman was responsible for chairing the Court’s Mental Health Subcommittee, which authored a ground-breaking report entitled, Transforming Florida’s Mental Health System. This report outlines recommendations with the goal of decreasing inappropriate and costly involvement of people with mental illnesses in the justice system. Since October 2010 Judge Leifman has chaired the Florida Supreme Court’s Task Force on Substance Abuse and Mental Health Issues in the Court. Due to his expertise in the areas of criminal justice and mental health, Judge Leifman has been appointed to serve in a variety of capacities on local, state, and national bodies, including Co-Chair of the Council of State Governments/TAPA Center for Jail Diversion Judges’ Criminal Justice/Mental Health Leadership Initiative, Co-Chair of the Miami-Dade County Mayor’s Mental Health Task Force, Board of Directors of the American Psychiatric Association Foundation, Board of Directors of the Corporation for Supportive Housing, member of the National Leadership Forum for Behavioral Health and Criminal Justice

continued on next page
Judge Steven Leifman (continued)

Services, member of the American Bar Association Task Force on Criminal Justice Mental Health Standards, Co-Chair of the American Bar Association Criminal Justice Mental Health Committee, Co-Chair of the Florida Bar Special Committee on Mental Health and a Voluntary Assistant Professor of Psychiatry and Behavioral Sciences at the University of Miami School of Medicine. In addition, Judge Leifman serves as Chair of the South Florida Behavioral Health Network and Finance Chair of the Miami-Dade Homeless Trust.

In recognition of his tireless efforts, Judge Leifman has received numerous awards including; the 2015 William H. Rehnquist Award for Judicial Excellence. One of the nation’s highest judicial honors, the Rehnquist Award is presented annually to a state court judge who exemplifies judicial excellence, integrity, fairness, and professional ethics. Chief Justice of the United States John G. Roberts Jr. presented the award to Judge Leifman during a ceremony at the U.S. Supreme Court in Washington, D.C. on November 19, 2015. Judge Leifman is also the first recipient to receive the Florida Supreme Court Chief Justice Award for Judicial Excellence (2015). Presented by the Chief Justice of the Florida Supreme Court, this prestigious award honors a state trial court judges who exemplify judicial excellence, including strength of character, integrity, fairness, open-mindedness, knowledge of the law, sound judgment, professional ethics, intellectual courage, compassion, and decisiveness.

More recently, Judge Leifman was named by New Times as one of Miami-Dade’s most interesting people of 2017 and he was named a 2016 Governing Magazine Public Official of the year. One of eight honorees, the award recognizes governmental leaders who exemplify the ideals of public service. In addition, Judge Leifman received the 2017 Legal Services of Miami Equal Justice Judicial Leadership Award and was the first recipient of the 2016 Group for the Advancement of Psychiatry (GAP) “Dear Abby Award,” the 2016 Greater Miami Chamber of Commerce Henry M. Flagler Community Builder Award, the 2016 Spanish American League Against Discrimination “Sense of Community Award,” a 2014 American Psychiatric Association Presidential Commendation, the 2014 Spero Award from Weill Cornell Medical College, the Dade County Bar Association 2014 Justice Louis Brandeis Award, the 2014 Lawyers To The Rescue Humanitarian Award, the Dade County Bar Association 2013 Criminal Justice Award, the Brain & Behavior Research Foundation 2012 Productive Lives Award, the Society of Biological Psychiatry 2012 Humanitarian Award.

Judge Leifman has also been featured in many national and local television programs, radio programs and articles regarding mental health and the criminal justice system including, The New England Journal of Medicine, the Atlantic Magazine, CBS News, USA Today, CNN: Anderson Cooper Special Report, CNN: Special Investigations Unit: The Criminally Insane, NBC Nightly News, PBS: Minds on the Edge, Facing Mental Illness, NPR: All Things Considered, New York Times, Washington Post, Wall Street Journal; Governing Magazine, the Samantha Bee Show on TBS, CBS4: The Forgotten Floor, WPLG- TV10: This Week in South Florida, WPBT2 South Florida PBS, Miami Herald and Miami Today. He has also authored and published numerous articles and book chapters on mental illnesses and the criminal justice system.
PLENARY SESSIONS

Thursday, 11 April
Regency P-Q

8:30 AM – 9:30 AM      Cognitive Behaviour Therapy for People with Psychosis
Tony Morrison

2:00 PM – 3:00 PM      Modeling the Impact of Rare and Common Variants in Schizophrenia Using Stem Cells
Kristen Brennand

Friday, 12 April
Regency P-Q

8:30 AM – 9:30 AM      Schizophrenia and Gluten: New Target and Precision Medicine
Deanna Kelly

2:00 PM – 3:00 PM      My Smartphone Can Do What?! Mobile Health and the Future of Mental Healthcare
Dror Ben-Zeev

Saturday, 13 April
Regency P-Q

8:30 AM – 9:30 AM      Schizophrenia in the Flesh: The Case for Behavioral Sciences in the Age of Big Data
Sohee Park

2:00 PM – 3:00 PM      International Collaborative Efforts in the ENIGMA Schizophrenia Working Group
Jessica Turner

Sunday, 14 April
Regency P-Q

8:30 AM – 9:30 AM      Schizophrenia and Substance Use Disorder: A Unifying Hypothesis
Jibran Khokhar, presenting on behalf of Alan Green
SYMPOSIA SESSIONS

The title and location of each symposium is indicated in the program mobile app. The presentations in each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presenter in each session. Symposia are scheduled:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 11 April</td>
<td>10:00 AM – 12:00 PM</td>
</tr>
<tr>
<td></td>
<td>3:30 PM – 5:30 PM</td>
</tr>
<tr>
<td>Friday, 12 April</td>
<td>10:00 AM – 12:00 PM</td>
</tr>
<tr>
<td></td>
<td>3:30 PM – 5:30 PM</td>
</tr>
<tr>
<td>Saturday, 13 April</td>
<td>10:00 AM – 12:00 PM</td>
</tr>
<tr>
<td>Sunday, 14 April</td>
<td>10:00 AM – 12:00 PM</td>
</tr>
</tbody>
</table>

ORAL PRESENTATIONS

Oral presentation sessions are scheduled on Saturday, 13 April from 3:15 PM – 5:15 PM and again from 5:30 PM – 7:30 PM. (*Note: Oral Session, *Exploring Genetic Mechanisms for Developing Schizophrenia*, will be held concurrent with symposia on Friday, 12 April from 3:30 PM – 5:30 PM.) Within the concurrent sessions, there are 8 individual presentations.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, 12 April</td>
<td>*3:30 PM – 5:30 PM</td>
</tr>
<tr>
<td>Saturday, 13 April</td>
<td>3:15 PM – 5:15 PM</td>
</tr>
<tr>
<td></td>
<td>5:30 PM – 7:30 PM</td>
</tr>
</tbody>
</table>

POSTERS

Three poster sessions have been scheduled. Presenters should put their poster up by 9:30 AM and remove the poster by 5:00 PM on the day it is scheduled. Poster presentations are grouped by general topic when possible. All three poster sessions are located in Regency S-V. Lunch will be served each day with the poster session. Poster viewing will be open until 5:00 PM.

E-Posters are available for viewing online at [www.SchizophreniaConference.org](http://www.SchizophreniaConference.org).

<table>
<thead>
<tr>
<th>Day</th>
<th>Session</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 11 April</td>
<td>Poster Session I</td>
<td>12:00 PM – 2:00 PM</td>
</tr>
<tr>
<td>Friday, 12 April</td>
<td>Poster Session II</td>
<td>12:00 PM – 2:00 PM</td>
</tr>
<tr>
<td>Saturday, 13 April</td>
<td>Poster Session III</td>
<td>12:00 PM – 2:00 PM</td>
</tr>
</tbody>
</table>
REFRESHMENT BREAKS
All registered individuals are invited. Coffee and light pastries are available Thursday through Sunday mornings at 8:00 AM. The morning break will be located in the Regency P-Q Foyer.

LUNCHEONS
Buffet lunch will be served Thursday through Saturday from 12:00 PM – 2:00 PM in Regency S-V during the poster sessions.